Dimensional Fund Advisors LP raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 19.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,855,036 shares of the company's stock after acquiring an additional 295,594 shares during the period. Dimensional Fund Advisors LP owned approximately 1.29% of Denali Therapeutics worth $37,805,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in DNLI. Sterling Capital Management LLC lifted its position in Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after buying an additional 885 shares during the period. KBC Group NV boosted its stake in shares of Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after buying an additional 2,731 shares during the last quarter. AlphaQuest LLC grew its holdings in shares of Denali Therapeutics by 177.1% in the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after acquiring an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. increased its position in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after acquiring an additional 2,436 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.
Denali Therapeutics Price Performance
Shares of DNLI stock traded down $0.04 during mid-day trading on Friday, hitting $14.39. The company had a trading volume of 1,367,985 shares, compared to its average volume of 1,092,248. The stock's 50 day moving average price is $14.27 and its 200-day moving average price is $20.04. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The company has a market capitalization of $2.09 billion, a P/E ratio of -5.21 and a beta of 1.49.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period last year, the firm posted ($0.68) EPS. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms have issued reports on DNLI. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. HC Wainwright reduced their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday. Morgan Stanley assumed coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 price target on the stock. Oppenheimer reduced their price objective on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Finally, Robert W. Baird lowered their target price on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $33.79.
Check Out Our Latest Stock Analysis on DNLI
About Denali Therapeutics
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
